<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00857116</url>
  </required_header>
  <id_info>
    <org_study_id>ALBP</org_study_id>
    <secondary_id>HLF-20060245</secondary_id>
    <nct_id>NCT00857116</nct_id>
  </id_info>
  <brief_title>Deworming Against Tuberculosis</brief_title>
  <official_title>The Impact of Deworming on Host Immunity and Clinical Outcome in Patients With Pulmonary Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Linkoeping University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Gondar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Armauer Hansen Research Institute, Ethiopia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Linkoeping University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether treatment against intestinal helminths in
      patients with pulmonary tuberculosis undergoing chemotherapy could improve the clinical
      outcome by enhancing host immunity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mycobacterium tuberculosis causing tuberculosis (TB) is a major global public health problem.
      Because of increasing multi drug resistance and the long treatment period of at least six
      months, new therapeutic options are urgently needed. In countries like Ethiopia where TB is
      endemic, chronic worm infection is also highly prevalent. Recent data support that helminth
      infection might limit the host response against TB by inhibition of the TH1-response that is
      crucial in controlling the disease. In this study we want to test the hypothesis that
      Albendazole treatment of patients coinfected with helminths and TB could improve clinical
      outcome in addition to chemotherapy against TB. Additionally we will investigate the
      immunological interactions between TB and chronic helminths infection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in TB-score compared to baseline (Wejse et al 2007)</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sputum smear conversion</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final outcome according to WHO</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in ELIspot pattern (IL5, IFN-gamma and IL-10)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological response (IgE, Eosinophils, CD4-count)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest X-ray improvement</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Albendazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Albendazole 400mg per os once daily for three consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 400mg per os for three consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albendazole</intervention_name>
    <description>Albendazole 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis</description>
    <arm_group_label>Albendazole</arm_group_label>
    <other_name>ALB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed and written consent to take part in the study

          -  Newly diagnosed pulmonary TB patients according to the WHO definitions of active
             tuberculosis who have a positive stool sample for helminths other than Schistosoma
             spp.

        Exclusion Criteria:

          -  Pregnancy

          -  Corticosteroid or antibiotic treatment

          -  Symptomatic (diarrhoea) infection caused by worm infection

          -  Chronic diseases or acute infectious diseases other than TB or HIV

          -  Stool sample positive for Schistosoma spp
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ebba Abate, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Gondar and Linkoeping University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ermias Diro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Gondar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Schoen, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Linkoeping University, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Gondar</name>
      <address>
        <city>Gondar, Region 3, Ethiopia</city>
        <state>Gondar</state>
        <country>Ethiopia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ethiopia</country>
  </location_countries>
  <reference>
    <citation>Borkow G, Bentwich Z. HIV and helminth co-infection: is deworming necessary? Parasite Immunol. 2006 Nov;28(11):605-12. Review.</citation>
    <PMID>17042932</PMID>
  </reference>
  <reference>
    <citation>Modjarrad K, Zulu I, Redden DT, Njobvu L, Lane HC, Bentwich Z, Vermund SH. Treatment of intestinal helminths does not reduce plasma concentrations of HIV-1 RNA in coinfected Zambian adults. J Infect Dis. 2005 Oct 1;192(7):1277-83. Epub 2005 Aug 25.</citation>
    <PMID>16136473</PMID>
  </reference>
  <reference>
    <citation>Kassu A, Mengistu G, Ayele B, Diro E, Mekonnen F, Ketema D, Moges F, Mesfin T, Getachew A, Ergicho B, Elias D, Wondmikun Y, Aseffa A, Ota F. HIV and intestinal parasites in adult TB patients in a teaching hospital in Northwest Ethiopia. Trop Doct. 2007 Oct;37(4):222-4.</citation>
    <PMID>17988484</PMID>
  </reference>
  <reference>
    <citation>Elias D, Akuffo H, Thors C, Pawlowski A, Britton S. Low dose chronic Schistosoma mansoni infection increases susceptibility to Mycobacterium bovis BCG infection in mice. Clin Exp Immunol. 2005 Mar;139(3):398-404.</citation>
    <PMID>15730384</PMID>
  </reference>
  <reference>
    <citation>Elias D, Mengistu G, Akuffo H, Britton S. Are intestinal helminths risk factors for developing active tuberculosis? Trop Med Int Health. 2006 Apr;11(4):551-8.</citation>
    <PMID>16553939</PMID>
  </reference>
  <reference>
    <citation>Elias D, Wolday D, Akuffo H, Petros B, Bronner U, Britton S. Effect of deworming on human T cell responses to mycobacterial antigens in helminth-exposed individuals before and after bacille Calmette-Gu√©rin (BCG) vaccination. Clin Exp Immunol. 2001 Feb;123(2):219-25.</citation>
    <PMID>11207651</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2009</study_first_submitted>
  <study_first_submitted_qc>March 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2009</study_first_posted>
  <last_update_submitted>August 28, 2013</last_update_submitted>
  <last_update_submitted_qc>August 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Linkoeping University</investigator_affiliation>
    <investigator_full_name>Thomas Schon</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>Deworming</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>TB-score</keyword>
  <keyword>Albendazole</keyword>
  <keyword>Helminths</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albendazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

